神経変性疾患におけるハーブおよびハーブミネラル製剤
Rashmi Baby Raj1, Vinodini Nithyananda Madom Anantharaya2, Nayanatara Arun Kumar2
1Department of Physiology, AHS, A. J. Institute of Medical Sciences and Research Centre, Manipal, India.
Annals of African medicine
|February 21, 2026
まとめ
薬草は治療の可能性を秘めているが,薬剤開発の課題に直面している. このレビューでは,新しい植物医学を開発するための歴史,課題,および潜在的な救済策を探索します.
科学分野:
- 薬理学 薬理学とは
- エスノボタニーはエスノボタニーを研究する.
- 自然製品化学 自然製品化学
背景:
- ハーブラーメディは,治療的可能性と患者の受け入れのためにますます認識されています.
- 植物から派生した植物薬は,使用の歴史が長いが,現代医学では極めて重要であり,薬物の50%は天然の源から由来している.
- 新しい薬の探求は,課題にもかかわらず,ハーブ薬への興味を新たにした.
研究 の 目的:
- 薬草および薬草ミネラル製剤の歴史的文脈をレビューする.
- 草原資源から新しい薬物を発見する際の課題と障害について議論する.
- 植物医学の開発を進めるための潜在的な解決策と救済策を探求する.
主な方法:
- 薬草に関する歴史的および現代的な研究の文献レビュー.
- 活性化合物,毒性,規制上のハードルの識別を含む植物医学薬の開発における課題の分析.
- これらの課題を克服するための潜在的な戦略の探求.
主要な成果:
- 漢方医学は豊かな歴史を持ち,現代の薬局に大きく貢献しています.
- 薬草資源からの薬剤発見は複雑で高価で,成功率は低い.
- 主要な課題は,活性抽出物の特定,毒性および副作用の評価,薬物相互作用の管理,規制要件をナビゲートすることです.
結論:
- 課題にもかかわらず,医薬品業界から新しい植物薬に対する関心が著しく増加しています.
- 特定,安全性,規制における障害を克服することは,ハーブ薬の開発を進めるために極めて重要です.
- 植物薬の潜在力を最大限に活用するためには,さらなる研究と戦略的アプローチが必要である.
関連する概念動画
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
716
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
716
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Neural Regulation
43.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.6K


